# A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults

> **NCT06452771** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 59 (actual)

## Conditions studied

- Healthy Volunteers With Hyperlipidemia

## Interventions

- **DRUG:** ALN-ANG3
- **DRUG:** Placebo (PB)

## Key facts

- **NCT ID:** NCT06452771
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-06-27
- **Primary completion:** 2026-12-04
- **Final completion:** 2026-12-04
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06452771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06452771, "A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06452771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*